



<b>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</b>	<i>Application No.</i>	09/991,971
	<i>Filing Date</i>	26 November 2001
	<i>First Named Inventor</i>	Markku AHOTUPA
	<i>Group Art Unit</i>	1644
	<i>Examiner Name</i>	P.N. Huynh
	<i>Attorney Docket No.</i>	2630-113
<i>Title of the Invention:</i> <b>METHOD OF INHIBITING OVERACTIVITY OF PHAGOCYTES OR LYMPHOCYTES IN AN INDIVIDUAL</b>		

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**RECEIVED**

Assistant Commissioner for Patents  
Washington, D.C. 20231


AUG 1 8 2003


TECH CENTER 1600/2900

Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith copies of additional publications that the Office may wish to consider in examination of the subject application. The publications are listed on the attached form PTO-1449.

I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. A copy of the International Search Report is also enclosed.

<b>RESPECTFULLY SUBMITTED,</b>					
<b>NAME AND REG. NUMBER</b>	Jeffrey L. Ihnen, Registration No. 28,957				
<b>SIGNATURE</b>				<b>DATE</b>	14 AUGUST 2003
<b>Address</b>	ROTHWELL, FIGG, ERNST & MANBECK, p.c. Suite 800, 1425 K Street, N.W.				
<b>City</b>	Washington	<b>State</b>	D.C.	<b>Zip Code</b>	20005
<b>Country</b>	U.S.A.	<b>Telephone</b>	202-783-6040	<b>Fax</b>	202-783-6031



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/991,971

Filing Date 26 November 2001

First Named Inventor Markku AHOTUPA

Group Art Unit 1644

Examiner Name P.N. Huynh

Attorney Docket Number 2630-113

Sheet

1

of

1

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>3</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	1	EP	0 906 761	A2	Archer Daniels Midland Company	07 April 1999	
	2	WO	02/080702	A1	Unilever N.V. et al.	17 October 2002	

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	3	CHO, Jae Youl et al. (1999). "Immunomodulatory Effect of Arctigenin, a Lignan Compound, on Tumour Necrosis Factor-alpha and Nitric Oxide Production and Lymphocyte Proliferation," <i>J. Pharm. Pharmacol.</i> 51:1267-1273.	
	4	YANG, Li-Ming et al. (1996). "Synthesis and Anti-HIV Activity of Dibenzylbutyrolactone Lignans," <i>Bioorganic &amp; Medicinal Chem. Letts.</i> 6(8):941-944.	
	5	CHO, Min Kyung et al. (2002). "Potent Inhibition of Lipopolysaccharide-Inducible Nitric Oxide Synthase Expression by Dibenzylbutyrolactone Lignans Through Inhibition of I-κ Bα Phosphorylation and of p65 Nuclear Translocation in Macrophages," <i>Intl. Immunopharmacol.</i> 2:105-116.	
	6	HIRANO, Toshihiko et al. (1994). "Natural Flavonoids and Lignans are Potent Cytostatic Agents Against Human Leukemic HL-60 Cells," <i>Life Sciences</i> 55(13):1061-1069.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

### \*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code.

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.